

Universal ultrasound screening and early treatment of developmental dysplasia of the hip: a critical review

Nabil Alassaf* 

1. Department of Orthopedic Surgery, Hail Health Cluster, Hail, Saudi Arabia

*Corresponding author

Nabil Alassaf
Department of Orthopedic Surgery,
Hail Health Cluster,
Hail, Saudi Arabia
E-mail: dr.nabil.alassaf@gmail.com

DOI

10.25122/jml-2024-0251

Dates

Received: 31 May 2024
Accepted: 2 August 2024

ABSTRACT

Developmental dysplasia of the hip (DDH) is the most common musculoskeletal disease in infants, and delayed diagnosis can worsen the prognosis. Clinical evidence increasingly supports universal ultrasound (US) screening over selective US screening. The Graf method remains the most widely accepted US technique. Performing an US screening at one month of age seems appropriate as it allows for some hip maturity and early detection, thereby increasing the chances of a favorable outcome. This paper presents an approach to US findings based on the femoral head coverage method. Considering the long-term cost and psychosocial impact of missed DDH cases, universal ultrasound screening appears to be a cost-effective alternative.

KEYWORDS: universal screening, selective screening, hip dysplasia, congenital hip dislocation, pediatric

INTRODUCTION

Developmental dysplasia of the hip (DDH) is a spectrum of pathologies ranging from mild, self-resolving dysplasia to irreducible dislocation. Its etiology is believed to involve genetic and mechanical factors, with key determinants including breech presentation, female gender, family history, and oligohydramnios [1,2]. Traditional swaddling methods, which adduct and extend the hips, increase the risk of hip dislocation, while other risk factors include being a firstborn child, high birth weight, foot deformities, and multiple pregnancies [3,4].

The incidence of DDH varies considerably based on the definition of dysplasia, detection method, and geographic location [5]. In a single hospital in the western province of Saudi Arabia, the incidence rate of DDH was found to be 12 per 1,000 live births when using ultrasound (US) screening following clinical assessment [6]. DDH is believed to be more prevalent among Gulf Cooperation Council nationals [7].

History and clinical examination alone are specific but not sensitive enough to screen DDH [8-10]. Meanwhile, ultrasound is 100% sensitive [11]. Screening for DDH is a form of secondary prevention. Harper *et al.* [12] found that experienced pediatric orthopedic surgeons mislabeled 14% of the dislocated hips as reduced based on physical examination alone. Kyung *et al.* [13] also noted significant inconsistency between clinical and US findings despite examinations by seasoned orthopedic surgeons.

The most commonly prescribed treatment for DDH during the first 6 months of life is the Pavlik harness (PH). The failure rate of PH varies widely, reported to be as low as 1.8% and as high as 29% in one study, where the success rate deteriorated

with age [1,14-15]. When splinting fails, or the child presents at more than approximately six months, reduction is usually done in the operating room. The age at the time of surgery is an independent predictor of the need for more invasive procedures [16,17]. Early treatment with an abduction splint leads to better outcomes compared to late presentation after the child begins walking [18].

Mass screening for DDH in infancy has been long recommended and linked to the degree of country development [19]. Despite growing clinical evidence, the topic remains controversial, with significant inter and intra-country differences. People in the high-risk group have a higher proportion of affected individuals, but the low-risk group probably has a larger number of cases. The Geoffrey Rose population-based prevention strategy takes this into account [20]. In other words, most cases will be missed when screening subjects with risk factors using a targeted approach. In comparison, the opposite is true when utilizing universal screening. Rose also quoted the term 'prevention paradox', indicating that a prevention measure that benefits the population has a small value for participating individuals, which lowers the motivation to participate. However, a population-based approach enhances the concept of equality in healthcare delivery [21].

Various imminent entities have released guidelines indicating that there is insufficient evidence to support universal US screening, such as the American Academy of Pediatrics (2000), The Canadian Task Force (2001), the United States Preventive Services Task Force (2006), Pediatric Orthopedic Society of North America (2007), European Society of Pediatric Radiology (2011) and more recently the American Academy of Orthopedic Surgeons (2014) [22-26]. Since the release of such guidelines, how-

ever, multiple studies have been published. This review aimed to re-examine and summarize peer-reviewed literature pertinent to the screening and early treatment of DDH.

Screening programs

To compare the efficacy of universal versus selective US screening for DDH, a MEDLINE search was conducted using the terms 'Screening' and 'DDH'. This comprehensive search was performed across all fields without filters, with the last search conducted in July 2024. Articles were selected based on their titles and abstracts, and references within these articles, as well as papers citing them, were assessed and reviewed.

Health authorities universally expect that routine neonatal physical exams include an assessment for DDH. There are two primary US screening techniques for early detection of DDH: a population-based mass approach, commonly known as universal screening, and a high-risk targeted approach, referred to as selective US screening. Universal ultrasound screening using the Graf method has been performed in at least six European countries, with the initial ultrasound conducted between the first and 90th day of life. Conversely, in Denmark, Greece, Hungary, and France, US screening is performed selectively based on the presence of risk factors and physical exam findings. However, the availability of high-quality clinical assessments may not be consistent [27,28].

Notably, 94% of the members of the Pediatric Orthopedic Society of North America believe that a universal screening program should not be adopted in the United States and that 'high-risk' selective screening is adequate. Interestingly, 13% of respondents reported over-referral of patients for suspected DDH, while the majority noted seeing DDH patients older than 1 year for their initial assessment [29]. A Cochrane review by Shorter *et al.* [30] in 2011 concluded that there is insufficient evidence to make clear recommendations for or against universal US screening [30]. Selective screening can be subjective and varies between clinicians, though it seems more effective in certain parts of the world. For example, in Sweden, the Swedish Pediatric Orthopedic Society has been auditing missed cases through a registry of late-diagnosed hip dislocations since 2000, considering DDH detection after two weeks of age as a late diagnosis. The incidence of late detection went down to 0.1 per 1000 live births from 0.9 per 1,000 live births [31]. Holen *et al.* concluded that universal ultrasound is not necessary in the presence of 'high quality' selective screening, and this was based on a randomized controlled trial (RCT) of 15,529 infants [32]. There was one late detection in the universal screening arm and five late detections in the selective screening group, which did not reach statistical difference [32]. Similarly, an RCT of 11,925 infants by Rosendahl *et al.* found fewer cases of late detection in the universal screening arm, though the difference was not statistically significant [33]. RCTs require clinical equipoise and are likely to show differences with larger samples. However, it remains uncertain if the controlled setting in RCTs is generalizable to broader clinical practice [34].

Clarke *et al.* reported on a selective screening program at a maternity hospital in the UK, where 19% of infants were screened by US based on clinical assessment, resulting in only 4.6% of DDH cases presenting after 3 months [35]. Another South Australian study noted that 2.4% of DDH cases presented after 3 months of age using a selective US screening approach, which included serial clinical assessments for DDH by trained staff until

the age of 2.5 years [36]. In a systematic review of observational studies by Kuitunen *et al.*, the authors concluded that universal screening has a higher rate of early detections and treated patients, but the incidence of late detection and surgical treatment was not significantly lower than with selective screening [37].

Kamath *et al.* failed to document a significant reduction in DDH late detection in the Greater Glasgow area, Scotland, UK, after the initiation of a selective US screening program [38]. In some health systems where selective US screening is chosen, the referral for hip US is high, probably because of the medico-legal risk [39,40]. An international multi-specialty panel of 24 experts strongly favored universal US screening as early as possible, before the sixth week of age, and agreed that universal US screening is cost-effective and does not lead to over-treatment. These experts reviewed current evidence before voting [2]. Johnson *et al.* [41] demonstrated that about 50% of DDH cases would be missed with a selective ultrasound approach, a finding similar to that of Ziegler *et al.* [10]. Gyurkovits *et al.* noted that about half of DDH patients did not exhibit any physical signs or risk factors other than female gender [42]. Using a universal screening approach, Buonsenso *et al.* [43] found that 19 out of the 48 (40%) pathologic hips had no risk factor or positive clinical findings. Talbot *et al.* [44] noted that 58% of irreducible hips presented late despite a selective screening program. In a meta-analysis by Laborie *et al.* [45], which included 511,403 patients, selective ultrasound screening was inferior to universal ultrasound in early detection of DDH [45]. This was similar to what was reported in an earlier meta-analysis by Jung and Jang [46]. In another review of 12 studies by Poacher *et al.* [47], selective screening did not reduce the rate of surgical intervention in the UK, which is 0.8/1000 live births. Furthermore, this approach has become less effective over the years, according to Sharrock *et al.* [48]. Broadhurst *et al.* studied the rate of late detection of DDH, defined as diagnosis after the age of one year, and found that the rate had not decreased over 35 years of a national selective screening program in the UK, and it increased from about 0.45 to 1.28 per 1,000 live births [49]. This concurred with the conclusions of other reports two decades earlier [50-52].

In Germany, universal ultrasound screening is recommended and provided for free for all newborns. If DDH is suspected, the US is performed during the first week of life; otherwise, it is scheduled between the ages of 4 to 6 weeks. Von Kries *et al.* [53] found that universal screening led to 50% fewer operative procedures in patients who complied with the recommendation compared to those who did not undergo universal US, aligning with earlier findings by Wirth *et al.* [54]. Thallinger *et al.* also noted that the universal screening program in Austria reduced pelvic osteotomies by 46% [55]. Sink *et al.* reviewed 68 skeletally mature patients with symptomatic hip dysplasia requiring corrective osteotomy and found that the current selective ultrasound screening program would miss 85% of those patients [56]. A summary of the evidence is outlined in Table 1.

Ultrasound techniques

Ultrasound remains superior to radiographs in diagnosing DDH in the first few months of life in terms of ionizing radiation exposure and accuracy [59]. The Graf method is considered the reference standard for ultrasound diagnosis of DDH and is performed with the hip flexed in a lateral decubitus position [27]. The alpha and beta angles, which are key to this method, are reliably interpreted by examiners, though the quality of the images can impact their

Table 1. Summary of systematic reviews and meta-analyses that compared universal with selective ultrasound screening during the last 20 years

Author, Study	Year	Description	Number of studies/ Participants	Conclusion
Laborie <i>et al.</i> [45]	2023	SRMA	16/511,403	Late detections are lower with UUS
Cheock <i>et al.</i> [57]	2023	SRMA	31	Late detections are lower with UUS
Kuitunen <i>et al.</i> [37]	2022	SRMA	76/16,901,079	Higher early detections with UUS
Pandey and Jojari [58]	2021	SR	34	Late detections are lower with UUS
Jung and Jang [46]	2020	SRMA	5/59,492	Late detections are lower with UUS
Shorter <i>et al.</i> [30]	2013	SR	2/23,530	Insufficient evidence

SR, systematic review; SRMA, systematic review and meta-analysis; UUS, universal ultrasound screening.

accuracy [60-62]. When combined with certain anthropometric data, automated ultrasound scanning shows promising clinical applications by minimizing the need for manual measurements [63]. Additionally, artificial intelligence-guided portable ultrasound image acquisition and reporting are being investigated to reduce costs and minimize false-positive referrals [64].

The femoral head coverage (FHC) method is another reliable technique for assessing DDH. It classifies hips as normal if the FHC is more than 50%, unstable if 40-49%, subluxated if 30-39%, and dislocated if less than 30% [65-67]. The American Academy of Orthopedic Surgeons defines FHC categories as normal ($\geq 45\%$), borderline (35-44%), or dysplastic ($< 35\%$). Husum *et al.* suggested a pubofemoral distance cut-off value of more than 4.4 mm to indicate dysplasia, with 100% sensitivity and 93% specificity for DDH [68].

Ultrasound timing

In Austria, universal US screening is performed at least twice: once during the first week of life and again between 6-8 weeks. In the Czech Republic, US is universally performed three times during the first three months [28]. Graf recommends conducting US screening before six weeks of age [69]. The American College of Radiology suggests that hip US should be done after four weeks of age [70], while both the American Institute of Ultrasound in Medicine and the American College of Radiology advise against performing hip US on infants younger than 3 to 4 weeks unless there are clinical signs of hip instability [71].

One main disadvantage of US screening after hospital discharge is that a certain percentage of infants may not be brought in for their US appointment [72]. For busy facilities, an after-hours US screening may reduce the load on the health system and minimize parent absence from work. A delay of treatment up to 6 weeks does not seem harmful [73], though the success rate of the PH decreases if treatment begins after six weeks [45,74,75]. Sanghrajka *et al.* [76] noted that none of the 55 patients who underwent open reduction had started PH treatment before six weeks. Therefore, infants ideally should be seen by a pediatric orthopedic service before 6 weeks of age.

Based on the literature, four weeks of age for infants who can reliably be brought to later US appointments appears most appropriate, allowing for some degree of hip maturity and an early appointment in the pediatric orthopedic clinic. Otherwise, doing US before discharging the infant is a viable alternative [55,77]. There is concern that early US may show many hips as pathologic, but a study of 21,676 newborns who underwent US screening

during the first week of life found that only 0.3% of the hips were pathologic [78]. Another study of 28,000 consecutive live births universally screened by US during the first few days of life reported no late DDH presentations within the first 5 years of life [79]. In a review by Sakkers and Pollet, Graf 2a hips have an 89% to 98% chance of spontaneous recovery, and the percentage deteriorates to less than 50% in Graf 4 [80]. When treatment is initiated for unstable hips, US needs to be repeated after two weeks [14], and an X-ray should be requested for treated patients before discharging them from the clinic [81]. A recent report by Hockett *et al.* found that premature birth does not influence hip maturity and thus does not affect US timing [82].

Early treatment

Monitoring borderline cases without treatment during the first three months of life can be justified. However, the parents need to be aware of the possible need for abduction bracing based on subsequent imaging [83]. In one study, investigators monitored 42 hips with a mean FHC of 39% at one month of age. At the 2-year follow-up, radiographs showed an acetabular index (AI) of 22 degrees, with none of the hips exceeding 30 degrees [84]. In an RCT by Pollet *et al.* [85], 80% of borderline dysplasia (Graf IIb/IIc) diagnosed at age 3-4 months normalized spontaneously. With active surveillance, the number of treated patients could be reduced, though there are concerns about losing follow-up, and some parents may not perceive the delay in treatment favorably. Therefore, treating these cases with more convenient splints like a Frejka pillow might be safer, as suggested by Blom *et al.* [86]. Zidka and Dzupa used a Frejka pillow for milder cases and the PH for the more unstable cases, noting higher non-compliance with the PH [15]. The decision to continue treatment should not be based solely on ultrasound; radiographic indices, particularly the acetabular index, must also normalize. [87-89]. Ultrasound results are best interpreted in the context of risk factors [90].

The author's preferred treatment approach is to apply a PH if FHC is less than 30% and use a Frejka pillow if FHC is 30% to 39%. For an FHC between 40% and 49%, treatment with a Frejka pillow is started if the child has significant risk factors like breech presentation, positive family history, oligohydramnios, and/or multiple gestations. Otherwise, the child is observed with no treatment, reassessed after 3 months of age, and managed accordingly. An FHC of 50% or more does not require further management and follow-up. Abduction splinting is continued until indices normalize on plain radiographs.

The burden of universal ultrasound screening

Over-treatment, if indeed an issue, is not the direct result of universal ultrasound screening. The clinician's understanding of the ultrasonic findings influences the decision to treat. Treatment of borderline cases, often referred to as 'stable hips', can be deferred until 3 to 4 months of age, when a radiograph can be obtained to confirm if the infant has an immature or dysplastic hip. The Cochrane review by Shorter *et al.* concluded that there is inconsistent evidence about whether universal ultrasound increases treatment [30].

Regarding the risk of avascular necrosis (AVN), Gahleitner *et al.* reviewed 60 patients over an average of 20.5 years following PH treatment, initiated and abandoned based on US findings. No AVN cases were reported, and only two hips showed residual dysplasia [91]. Rosendahl reported using Frejka pillow in approximately 1,200 infants with no resulting AVN [92].

Graf noted that the cost of screening and subsequent treatment is 33% less than the cost of treatment before the universal US screening program [69]. It is helpful to understand that reducing late detections means less prolonged spica casting, open reductions, pelvic and femoral osteotomies, revision open reductions, AVN, stiffness, leg length discrepancies, and early hip replacements. Therefore, a precise cost-benefit analysis is challenging, and the argument is more ethical. Studies often overlook the psychosocial impact and long-term costs.

Thaler *et al.* compared two five-year periods in the province of Tyrol, Austria. During the first period (1978 to 1982), screening was solely based on clinical examination before the widespread use of the Graf ultrasound method. In the second period (1993 to 1997), universal ultrasound screening was established. They noted an overall cost increase of €57,000 per annum in the second period but a seventy-six percent reduction in treatment interventions [93]. Clegg *et al.* in Coventry, UK, found that the overall cost of universal screening is comparable to that of surgical treatment [92]. This conclusion is similar to that of Rosendahl *et al.* in Bergen, Norway, who also noted that the cost of screening decreased over time following the implementation of universal US screening [94]. Woodacre *et al.* studied a regional selective ultrasound screening program with referrals to a hip dysplasia clinic in Exeter, UK. They found that 19% of cases were missed by the program and presented later than three months. The cost of US screening was £56/child, while the average cost of surgery was £4,352/child [95].

CONCLUSION

Universal US screening using the Graf method is justified and facilitates early detection and treatment, hence providing a better prognosis with no or minimal long-term added cost. Over-treatment can be avoided by a better understanding of US findings and by using treatment protocols that allow observation of milder forms of ultrasonographic hip dysplasia.

Conflict of interest

The author declares no conflict of interest.

Authorship

NA conceptualized the review, conducted the database searches, and wrote and edited the manuscript. The author read and approved the final manuscript.

REFERENCES

- Omeroglu H, Kose N, Akceylan A. Success of Pavlik Harness Treatment Decreases in Patients \geq 4 Months and in Ultrasonographically Dislocated Hips in Developmental Dysplasia of the Hip. *Clin Orthop Relat Res.* 2016 May;474(5):1146–52. doi.org/10.1007/s11999-015-4388-5
- O'Beirne JG, Chlapoutakis K, Alshryda S, Aydingoz U, Baumann T, Casini C, *et al.* International Interdisciplinary Consensus Meeting on the Evaluation of Developmental Dysplasia of the Hip. *Ultraschall Med.* 2019 Aug;40(4):454–64. doi.org/10.1055/a-0924-5491
- Salter RB. Etiology, pathogenesis and possible prevention of congenital dislocation of the hip. *Can Med Assoc J.* 1968 May 18;98(20):933–45.
- van Sleuwen BE, Engelberts AC, Boere-Boonekamp MM, Kuis W, Schulpen TWJ, L'Hoir MP. Swaddling: a systematic review. *Pediatrics.* 2007 Oct;120(4):e1097–106. doi.org/10.1542/peds.2006-2083
- Loder RT, Skopelja EN. The epidemiology and demographics of hip dysplasia. *ISRN Orthop.* 2011;2011:238607. doi.org/10.5402/2011/238607
- Almutairi FF. Incidence and characteristics of developmental dysplasia of the hip in a Saudi population: A comprehensive retrospective analysis. *Medicine.* 2024 Feb 9;103(6):e36872. doi.org/10.1097/MD.00000000000036872
- Dordevic N. Universal in-house neonatal hips ultrasonography screening in the United Arab Emirates. *Saudi Med J.* 2023 Nov;44(11):1120–6. doi.org/10.15537/smj.2023.44.11.20230444
- Chavoshi M, Soltani G, Shafiei Zargar S, Wyles CC, Kremers HM, Rouzrokh P. Diagnostic Performance of Clinical Examination Versus Ultrasonography in the Detection of Developmental Dysplasia of Hip: A Systematic Review and Meta-Analysis. *Arch Bone Jt Surg.* 2022 May;10(5):403–12. doi.org/10.22038/ABJS.2021.60504.2984
- Husum H-C, Ghaffari A, Ryttoft LA, Svendsen J, Harving S, Kold S, *et al.* Positive predictive values in clinical screening for developmental dysplasia of the hip. *Acta Paediatr.* 2021 Aug;110(8):2430–4. doi.org/10.1111/apa.15896
- Ziegler CM, Ertl KM, Delius M, Foerster KM, Crispin A, Wagner F, *et al.* Clinical examination and patients' history are not suitable for neonatal hip screening. *J Child Orthop.* 2022 Feb;16(1):19–26. doi.org/10.1177/18632521221080472
- Yu RX, Gunaseelan L, Malik AS, Arulchelvan A, Yue E, Siddiqua A, *et al.* Utility of Clinical and Ultrasonographic Hip Screening in Neonates for Developmental Dysplasia of the Hip. *Cureus.* 2021 Oct;13(10):e18516. doi.org/10.7759/cureus.18516
- Harper P, Joseph BM, Clarke NMP, Herrera-Soto J, Sankar WN, Schaeffer EK, *et al.* Even Experts Can Be Fooled: Reliability of Clinical Examination for Diagnosing Hip Dislocations in Newborns. *J Pediatr Orthop.* 2020 Sep;40(8):408–12. doi.org/10.1097/BPO.0000000000001602
- Kyung BS, Lee SH, Jeong WK, Park SY. Disparity between Clinical and Ultrasound Examinations in Neonatal Hip Screening. *Clin Orthop Surg.* 2016 Jun;8(2):203–9. doi.org/10.4055/cios.2016.8.2.203
- Dragonas CG, Kottaridou E, Vampertzi T, Abbakr L, Taha N, Manoukian D. Length of treatment and ultrasound timing in infants with developmental dysplasia of the hip. *Eur J Orthop Surg Traumatol.* 2024 Feb;34(2):1079–86. doi.org/10.1007/s00590-023-03771-z
- Zidka M, Džupa V. Pavlik harness and Frejka pillow: compliance affects results of outpatient treatment. *Arch Orthop Trauma Surg.* 2019 Nov;139(11):1519–24. doi.org/10.1007/s00402-019-03179-7
- Alassaf N. Prediction of the requirement of open reduction for developmental dysplasia of the hip. *J Int Med Res.* 2018 Jan;46(1):54–61. doi.org/10.1177/0300060517717357
- Alassaf N. Predictors of femoral shortening for pediatric developmental hip dysplasia surgery: an observational study in 435 patients. *Patient Saf Surg.* 2018;12:29. doi.org/10.1186/s13037-018-0176-y
- St George J, Kulkarni V, Bellemore M, Little DG, Birke O. Importance of early diagnosis for developmental dysplasia of the hip: A 5-year radiological outcome study comparing the effect of early and late diagnosis. *J Paediatr Child Health.* 2021 Jan;57(1):41–5. doi.org/10.1111/jpc.15111
- Wilson JMG, Jungner G, editors. Principles and Practice of Screening for Disease. Public health paper 34, Geneva, Switzerland; World Health Organization; 1968.
- Rose G. Sick individuals and sick populations. *Int J Epidemiol.* 1985 Mar;14(1):32–8. doi.org/10.1093/ije/14.1.32
- McLaren L. In defense of a population-level approach to prevention: why public health matters today. *Can J Public Health.* 2019 Jun;110(3):279–84. doi.org/10.17269/s41997-019-00198-0
- Lehmann HP, Hinton R, Morello P, Santoli J. Developmental dysplasia of the hip practice guideline: technical report. Committee on Quality Improvement, and Subcommittee on Developmental Dysplasia of the Hip. Vol. 105, *Pediatrics.* 2000 Apr p. E57. doi.org/10.1542/peds.105.4.e57
- Patel H, Canadian Task Force on Preventive Health Care. Preventive health care, 2001 update: screening and management of developmental dysplasia of the hip in newborns. *CMAJ.* 2001 Jun 12;164(12):1669–77.
- Shipman SA, Helfand M, Moyer VA, Yawn BP. Screening for developmental dysplasia of the hip: a systematic literature review for the US Preventive Services Task Force. *Pediatrics.* 2006 Mar;117(3):e557–76. doi.org/10.1542/peds.2005-1597

25. Schwend RM, Schoenecker P, Richards BS, Flynn JM, Vitale M, Pediatric Orthopaedic Society of North America. Screening the newborn for developmental dysplasia of the hip: now what do we do? *J Pediatr Orthop*. 2007 Sep;27(6):607–10. doi.org/10.1097/BPO.0b013e318142551e
26. Mulpuri K, Song KM. AAOS Clinical Practice Guideline: Detection and Nonoperative Management of Pediatric Developmental Dysplasia of the Hip in Infants up to Six Months of Age. *J Am Acad Orthop Surg*. 2015 Mar;23(3):206–7. doi.org/10.5435/JAAOS-D-15-00008
27. Graf R. The diagnosis of congenital hip-joint dislocation by the ultrasonic Combound treatment. *Arch Orth Trauma Surg*. 1980;97(2):117–33. doi.org/10.1007/BF00450934
28. Krysta W, Dudek P, Pulik Ł, Łęgosz P. Screening of Developmental Dysplasia of the Hip in Europe: A Systematic Review. *Children (Basel)*. 2024 Jan 13;11(1). doi.org/10.3390/children11010097
29. Taylor IK, Burile JE, Schaeffer EK, Geng X, Habib E, Mulpuri K, *et al*. Developmental Dysplasia of the Hip: An Examination of Care Practices of Pediatric Orthopaedic Surgeons in North America. *J Pediatr Orthop*. 2020 Apr;40(4):e248–55. doi.org/10.1097/BPO.0000000000001505
30. Shorter D, Hong T, Osborn DA. Cochrane Review: Screening programmes for developmental dysplasia of the hip in newborn infants. *Evid Based Child Health*. 2013 Jan;8(1):11–54. doi.org/10.1002/ebch.1891
31. Wenger D, Dümpe H, Nilsson J-Å, Tiderius CJ. Incidence of Late-Diagnosed Hip Dislocation After Universal Clinical Screening in Sweden. *JAMA Netw Open*. 2019 Nov 1;2(11):e1914779–9. doi.org/10.1001/jamanetworkopen.2019.14779
32. Holen KJ, Tegnander A, Bredland T, Johansen OJ, Saether OD, Eik-Nes SH, *et al*. Universal or selective screening of the neonatal hip using ultrasound? A prospective, randomised trial of 15,529 newborn infants. *J Bone Joint Surg Br*. 2002 Aug;84(6):886–90. doi.org/10.1302/0301-620X.84B6.0840886
33. Rosendahl K, Markestad T, Lie RE. Ultrasound screening for developmental dysplasia of the hip in the neonate: the effect on treatment rate and prevalence of late cases. *Pediatrics*. 1994 Jul;94(1):47–52.
34. Demetriou C, Hu L, Smith TO, Hing CB. Hawthorne effect on surgical studies. *ANZ J Surg*. 2019 Dec;89(12):1567–76. doi.org/10.1111/ans.15475
35. Clarke NMP, Reading IC, Corbin C, Taylor CC, Bochmann T. Twenty years experience of selective secondary ultrasound screening for congenital dislocation of the hip. *Arch Dis Child*. 2012 May;97(5):423–9. doi.org/10.1136/archdischild-2011-301085
36. Chan A, Cundy PJ, Foster BK, Keane RJ, Byron-Scott R. Late diagnosis of congenital dislocation of the hip and presence of a screening programme: South Australian population-based study. *Lancet*. 1999 Oct 30;354(9189):1514–7. doi.org/10.1016/S0140-6736(98)12469-8
37. Kuitunen I, Uimonen MM, Haapanen M, Sund R, Helenius I, Pönkiläinen VT. Incidence of Neonatal Developmental Dysplasia of the Hip and Late Detection Rates Based on Screening Strategy: A Systematic Review and Meta-analysis. *JAMA Netw Open*. American Medical Association; 2022 Aug 1;5(8):e2227638–8. doi.org/10.1001/jamanetworkopen.2022.27638
38. Kamath S, Mehdi A, Wilson N, Duncan R. The lack of evidence of the effect of selective ultrasound screening on the incidence of late developmental dysplasia of the hip in the Greater Glasgow Region. *J Pediatr Orthop B*. 2007 May;16(3):189–91. doi.org/10.1097/01.bpb.0000236229.44819.43
39. Choudry QA, Paton RW. Neonatal screening and selective sonographic imaging in the diagnosis of developmental dysplasia of the hip. *Bone Joint J*. 2018 Jun 1;100-B(6):806–10. doi.org/10.1302/0301-620X.100B6.BJJ-2017-1389.R1
40. Shaw BA, Segal LS. Evaluation and Referral for Developmental Dysplasia of the Hip in Infants. *Pediatrics*. 2016 Dec;138(6). doi.org/10.1542/peds.2016-3107
41. Johnson MD, Kuschel C, Donnan L. Neonatal clinical examination and selective ultrasound screening are not reliable for the early diagnosis of hip dysplasia: A retrospective cohort study. *J Paediatr Child Health*. 2023 Oct;59(10):1146–51. doi.org/10.1111/jpc.16472
42. Gyurkovits Z, Sohárg G, Baricsa A, Németh G, Orvos H, Dubs B. Early detection of developmental dysplasia of hip by ultrasound. *Hip Int*. 2021 May;31(3):424–9. doi.org/10.1177/1120700019879687
43. Buonsenso D, Curatola A, Lazzareschi I, Panza G, Morello R, Marocco R, *et al*. Developmental dysplasia of the hip: real world data from a retrospective analysis to evaluate the effectiveness of universal screening. *J Ultrasound*. 2021 Dec;24(4):403–10. doi.org/10.1007/s40477-020-00463-w
44. Talbot C, Adam J, Paton R. Late presentation of developmental dysplasia of the hip : a 15-year observational study. *Bone Joint J*. 2017 Sep;99-B(9):1250–5. doi.org/10.1302/0301-620X.99B9.BJJ-2016-1325.R1
45. Laborie LB, Rosendahl K, Dhoub A, Simoni P, Tomà P, Offiah AC. The effect of selective ultrasound screening on the incidence of late presentation of developmental hip dysplasia—a meta-analysis. *Pediatr Radiol*. Springer Berlin Heidelberg; 2023 Sep 9;53(10):1977–88. doi.org/10.1007/s00247-023-05666-x
46. Jung HW, Jang WY. Effectiveness of different types of ultrasonography screening for developmental dysplasia of the hip: A meta-analysis. *Medicine*. 2020 Dec 11;99(50):e23562. doi.org/10.1097/MD.00000000000023562
47. Poacher AT, Hathaway I, Crook DL, Froud JJ, Scourfield L, James C, *et al*. The impact of the introduction of selective screening in the UK on the epidemiology, presentation, and treatment outcomes of developmental dysplasia of the hip. *Bone Jt Open*. 2023 Aug 23;4(8):635–42. doi.org/10.1302/2633-1462.48.BJO-2022-0158.R1
48. Sharrock MN, Whelton CR, Paton RW. Selective sonographic screening for developmental dysplasia of the hip - increasing trends in late diagnosis. *Acta Orthop Belg*. 2023 Mar;89(1):15–9. doi.org/10.52628/89.1.8636
49. Broadhurst C, Rhodes AML, Harper P, Perry DC, Clarke NMP, Aarvold A. What is the incidence of late detection of developmental dysplasia of the hip in England?: a 26-year national study of children diagnosed after the age of one. *Bone Joint J*. 2019 Mar;101-B(3):281–7. doi.org/10.1302/0301-620X.101B3.BJJ-2018-1331.R1
50. Godward S, Dezateux C. Surgery for congenital dislocation of the hip in the UK as a measure of outcome of screening MRC Working Party on Congenital Dislocation of the Hip. Medical Research Council. *Lancet*. 1998 Apr 18;351(9110):1149–52. doi.org/10.1016/S0140-6736(97)10466-4
51. Zenios M, Wilson B, Galasko CS. The effect of selective ultrasound screening on late presenting DDH. *J Pediatr Orthop B*. 2000 Oct;9(4):244–7. doi.org/10.1097/01202412-200010000-00006
52. Paton RW, Hossain S, Eccles K. Eight-year prospective targeted ultrasound screening program for instability and at-risk hip joints in developmental dysplasia of the hip. *J Pediatr Orthop*. 2002;22(3):338–41. doi.org/10.1097/01241398-200205000-00013
53. Kries von R, Ilme N, Altenhofen L, Niethard FU, Krauspe R, Rückinger S. General ultrasound screening reduces the rate of first operative procedures for developmental dysplasia of the hip: a case-control study. *J Pediatr*. 2012 Feb;160(2):271–5. doi.org/10.1016/j.jpeds.2011.08.037
54. Wirth T, Stratmann L, Hinrichs E. Evolution of late presenting developmental dysplasia of the hip and associated surgical procedures after 14 years of neonatal ultrasound screening. *J Bone Joint Surg Br*. 2004 May;86(4):585–9. doi.org/10.1302/0301-620X.86B4.14586
55. Thallinger C, Pospischill R, Ganger R, Radler C, Krall C, Grill F. Long-term results of a nationwide general ultrasound screening system for developmental disorders of the hip: the Austrian hip screening program. *J Child Orthop*. 2014 Feb;8(1):3–10. doi.org/10.1007/s11832-014-0555-6
56. Sink EL, Ricciardi BF, Torre KD, Price CT. Selective ultrasound screening is inadequate to identify patients who present with symptomatic adult acetabular dysplasia. *J Child Orthop*. 2014 Dec;8(6):451–5. doi.org/10.1007/s11832-014-0620-1
57. Cheok T, Smith T, Wills K, Jennings MP, Rawat J, Foster B. Universal screening may reduce the incidence of late diagnosis of developmental dysplasia of the hip : a systematic review and meta-analysis. *Bone Joint J*. 2023 Feb;105-B(3):198–208. doi.org/10.1302/0301-620X.105B2.BJJ-2022-0896.R1
58. Pandey RA, Johari AN. Screening of Newborns and Infants for Developmental Dysplasia of the Hip: A Systematic Review. *Indian J Orthop*. 2021 Dec;55(6):1388–1401. doi.org/10.1007/s43465-021-00409-2
59. Sari AS, Karakuş Ö. The assessment of the efficacy of radiography in diagnosing developmental dysplasia of the hip in infants younger than six months with reference to hips graded by Graf classification using ultrasonography. *Eur Rev Med Pharmacol Sci*. 2024 Jan;28(1):71–9. doi.org/10.26355/eurev_202401_34892
60. Jomha NM, Mckvor J, Sterling G. Ultrasonography in developmental hip dysplasia. *J Pediatr Orthop*. 1995;15(1):101–4. doi.org/10.1097/01241398-199501000-00022
61. Pedrotti L, Crivellari I, Degrate A, De Rosa F, Ruggiero F, Mosconi M. Interpreting neonatal hip sonography: intraobserver and interobserver variability. *J Pediatr Orthop B*. 2020 May;29(3):214–8. doi.org/10.1097/BPB.0000000000000670
62. Walter SG, Ossendorff R, Yagdiran A, Hockmann J, Bornemann R, Placzek S. Four decades of developmental dysplastic hip screening according to Graf: What have we learned? *Front Pediatr*. 2022;10:990806. doi.org/10.3389/fped.2022.990806
63. Chen Y-P, Fan T-Y, Chu C-C, Lin J-J, Ji C-Y, Kuo C-F, *et al*. Automatic and human level Graf's type identification for detecting developmental dysplasia of the hip. *Biomed J*. 2023 Jun 10;47(2):100614. doi.org/10.1016/j.bj.2023.100614
64. Jaremkó JL, Harendranathan A, Bolouri SES, Frey RF, Dulai S, Bailey AL. AI aided workflow for hip dysplasia screening using ultrasound in primary care clinics. *Sci Rep*. Nature Publishing Group; 2023 Jun 7;13(1):9224–6. doi.org/10.1038/s41598-023-35603-9
65. Morin C, Harcke HT, MacEwen GD. The infant hip: real-time US assessment of ac-etabular development. *Radiology*. 1985 Dec;157(3):673–7. doi.org/10.1148/radiology.157.3.3903854
66. Holen KJ, Terjesen T, Tegnander A, Bredland T, Saether OD, Eik-Nes SH. Ultrasound screening for hip dysplasia in newborns. *J Pediatr Orthop*. 1994;14(5):667–73. doi.org/10.1097/01241398-199409000-00022
67. Häberg O, Foss OA, Gundersen T, Bjerkestrand Lian Ø, Slettvåg Hoel M, Holen KJ. The incidence of late-detected developmental dysplasia of the hip and its functional outcomes: a 17-year cohort study using selective ultrasound screening. *Acta Orthop*. 2023 Dec 11;94:588–93. doi.org/10.2340/17453674.2023.24578
68. Husum H-C, Hellfritsch MB, Hardgrib N, Møller-Madsen B, Rahbek O. Suggestion for new 4.4mm pubo-femoral distance cut-off value for hip instability in lateral position during DDH screening. *Acta Orthop*. 2019 Feb;90(1):88–93. doi.org/10.1080/17453674.2018.1554404
69. Graf R. Hip sonography: background; technique and common mistakes; results; debate and politics; challenges. *Hip Int*. 2017 May 12;27(3):215–9. doi.org/10.5301/hipint.5000514
70. Expert Panel on Pediatric Imaging, Nguyen JC, Dorfman SR, Rigsby CK, Iyer RS, Alazraki AL, *et al*. ACR Appropriateness Criteria® Developmental Dysplasia of the Hip-Child. Vol. 16, *J Am Coll Radiol*. 2019. pp. S94–S103. doi.org/10.1016/j.jacr.2019.02.014
71. American Institute of Ultrasound in Medicine, American College of Radiology. AIUM practice guideline for the performance of an ultrasound examination for

- detection and assessment of developmental dysplasia of the hip. Vol. 28, J Ultrasound Med. 2009. pp. 114–9. doi.org/10.7863/jum.2009.28.1.114
72. Marks DS, Clegg J, al-Chalabi AN. Routine ultrasound screening for neonatal hip instability. Can it abolish late-presenting congenital dislocation of the hip? *J Bone Joint Surg Br.* 1994 Jul;76(4):534–8. doi.org/10.1302/0301-620X.76B4.8027134
 73. Dwan K, Kirkham J, Paton RW, Morley E, Newton AW, Perry DC. Splinting for the non-operative management of developmental dysplasia of the hip (DDH) in children under six months of age. *Cochrane Database Syst Rev.* 2022 Oct 10;10(10):CD012717. doi.org/10.1002/14651858.CD012717.pub2
 74. Viere RG, Birch JC, Herring JA, Roach JW, Johnston CE. Use of the Pavlik harness in congenital dislocation of the hip. An analysis of failures of treatment. *J Bone Joint Surg Am.* 1990 Feb;72(2):238–44. doi.org/10.2106/0004623-199072020-00011
 75. He J, Chen T, Lyu X. Analysis of the results of hip ultrasonography in 48666 infants and efficacy studies of conservative treatment. *J Clin Ultrasound.* 2023 May;51(4):656–62. doi.org/10.1002/jcu.23439
 76. Sanghrajka AP, Murnaghan CF, Shekheris A, Eastwood DM. Open reduction for developmental dysplasia of the hip: failures of screening or failures of treatment? *Ann R Coll Surg Engl.* 2013 Mar;95(2):113–7. doi.org/10.1308/003588413X13511609957137
 77. Farr S, Grill F, Müller D. [When is the optimal time for hip ultrasound screening?]. *Orthopäde.* 2008 Jun;37(6):532–534–6–538–40. doi.org/10.1007/s00132-008-1236-2
 78. Treiber M, Korpar B, Sirše M, Merc M. Early neonatal universal ultrasound screening for developmental dysplasia of the hip: a single institution observational study. *Int Orthop.* 2021 Apr;45(4):991–5. doi.org/10.1007/s00264-020-04915-0
 79. Biedermann R, Riccabona J, Giesinger JM, Brunner A, Liebensteiner M, Wansch J, et al. Results of universal ultrasound screening for developmental dysplasia of the hip: a prospective follow-up of 28 092 consecutive infants. *Bone Joint J.* 2018 Oct;100-B(10):1399–404. doi.org/10.1302/0301-620X.100B10.BJJ-2017-1539.R2
 80. Sakkars R, Pollet V. The natural history of abnormal ultrasound findings in hips of infants under six months of age. *J Child Orthop.* 2018 Aug 1;12(4):302–7. doi.org/10.1302/1863-2548.12.180056
 81. Dormacher D, Lutz B, Freitag T, Sgroi M, Taurman R, Reichel H. Residual dysplasia of the hip after successful ultrasound-monitored treatment: how does an infant's hip evolve? *J Pediatr Orthop B.* 2022 Nov 1;31(6):524–31. doi.org/10.1097/BPB.0000000000000984
 82. Hockett C, Mayfield LM, Gill CS, Kim HKW, Sucato DJ, Podeszwa DA, et al. Does Screening Ultrasound Timing in Developmental Dysplasia of the Hip Need to be Adjusted for Moderate Preterm and Near-term Infants: A Prospective Study. *J Pediatr Orthop.* 2024 Jan 1;44(1):e25–9. doi.org/10.1097/BPO.00000000000002540
 83. Terjesen T, Holen KJ, Tegnander A. Hip abnormalities detected by ultrasound in clinically normal newborn infants. *J Bone Joint Surg Br.* 1996 Jul;78(4):636–40. doi.org/10.1302/0301-620X.78B4.0780636
 84. Kim HKW, Beckwith T, La Rocha De A, Zepeda E, Jo CH, Sucato D. Treatment Patterns and Outcomes of Stable Hips in Infants With Ultrasoundic Dysplasia. *J Am Acad Orthop Surg.* 2019 Jan 15;27(2):68–74. doi.org/10.5435/JAAOS-D-17-00233
 85. Pollet V, Castelein RM, van de Sande M, Witbreuk M, Mostert AK, Besselaar A, et al. Abduction treatment in stable hip dysplasia does not alter the acetabular growth: results of a randomized clinical trial. *Sci Rep.* 2020 Jun 15;10(1):9647–7. doi.org/10.1038/s41598-020-66634-1
 86. Blom HC, Heldaa O, Manoharan P, Andersen BD, Soia L. [Ultrasound screening for hip dysplasia in newborns and treatment with Frejka pillow]. *Tidsskr Nor Laegeforen.* 2005 Aug 11;125(15):1998–2001.
 87. Upasani VV, Bomar JD, Fitzgerald RE, Schupper AJ, Kelley SP. International Hip Dysplasia Registry. Prolonged Brace Treatment Does Not Result in Improved Acetabular Indices in Infantile Dislocated Hips. *J Pediatr Orthop.* 2022 May;42(5):e409–13. doi.org/10.1097/BPO.00000000000002110
 88. Atalar H, Günay C, Atik OŞ. Is treatment termination safe in developmental dysplasia of the hip following ultrasonographic normalization? *Eklemler Hastalıkları Cerrahisi.* 2021;32(2):521–2. doi.org/10.52312/jdrs.2021.206
 89. Morris AR, Thomas JMC, Reading IC, Clarke NMP. Does Late Hip Dysplasia Occur After Normal Ultrasound Screening in Breech Babies? *J Pediatr Orthop.* 2019 Apr;39(4):187–92. doi.org/10.1097/BPO.0000000000000903
 90. Bakti K, Lankinen V, Helminen M, Välpakka J, Laivuori H, Hyvärinen A. Clinical and sonographic improvement of developmental dysplasia of the hip: analysis of 948 patients. *J Orthop Surg Res.* 2022 Dec 12;1–8. doi.org/10.1186/s13018-022-03432-7
 91. Gahleitner M, Pisecky L, Gotterbarm T, Högl W, Luger M, Klotz MC. Long-term Results of Developmental Hip Dysplasia Under Therapy With Pavlik Harness. *J Pediatr Orthop.* 2024 Mar 1;44(3):135–40. doi.org/10.1097/BPO.00000000000002575
 92. Rosendahl K. The effect of ultrasound screening on late developmental dysplasia of the hip. *Arch Pediatr Adolesc Med.* 1995 Jun;149(6):706–7. doi.org/10.1001/archpedi.1995.02170190116026
 93. Thaler M, Biedermann R, Lair J, Krismir M, Landauer F. Cost-effectiveness of universal ultrasound screening compared with clinical examination alone in the diagnosis and treatment of neonatal hip dysplasia in Austria. *J Bone Joint Surg.* 2011 Aug;93(8):1126–30. doi.org/10.1302/0301-620X.93B8.25935
 94. Clegg J, Bache CE, Raut VV. Financial justification for routine ultrasound screening of the neonatal hip. *J Bone Joint Surg Br.* 1999 Sep;81(5):852–7. doi.org/10.1302/0301-620X.81B5.9746
 95. Woodacre T, Dhadwal A, Ball T, Edwards C, Cox PJA. The costs of late detection of developmental dysplasia of the hip. *J Child Orthop.* 2014 Aug;8(4):325–32. doi.org/10.1007/s11832-014-0599-7